Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ASP2138 |
Synonyms | |
Therapy Description |
ASP2138 is a bispecific antibody that targets Claudin 18.2 (CLDN18.2) expressed on tumor cells and CD3 on T-cells, which potentially leads to activation of cytotoxic T-lymphocytes and killing of tumor cells expressing CLDN18.2 (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ASP2138 | ASP-2138|ASP 2138 | CD3 Antibody 75 CLDN18.2 Antibody 13 | ASP2138 is a bispecific antibody that targets Claudin 18.2 (CLDN18.2) expressed on tumor cells and CD3 on T-cells, which potentially leads to activation of cytotoxic T-lymphocytes and killing of tumor cells expressing CLDN18.2 (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05365581 | Phase I | ASP2138 | A Study of ASP2138 in Adults With Stomach Cancer or Pancreatic Cancer | Recruiting | USA | 1 |